{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:50:03Z","timestamp":1794451803867,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Treatment failure occurs in about 25% of patients with methicillin-susceptible <jats:italic>Staphylococcus<\/jats:italic>\u2009<jats:italic>aureus<\/jats:italic> (MSSA) bacteremia. We assessed whether cloxacillin plus fosfomycin achieves better treatment success than cloxacillin alone in hospitalized adults with MSSA bacteremia. We conducted a multicenter, open-label, phase III\u2013IV superiority randomized clinical trial. We randomly assigned patients (1:1) to receive 2\u2009g of intravenous cloxacillin alone every 4\u2009h or with 3\u2009g of intravenous fosfomycin every 6\u2009h for the initial 7\u2009days. The primary endpoint was treatment success at day 7, a composite endpoint with the following criteria: patient alive, stable or with improved quick Sequential Organ Failure Assessment score, afebrile and with negative blood cultures for MSSA, adjudicated by an independent committee blinded to treatment allocation. We randomized 215 patients, of whom 105 received cloxacillin plus fosfomycin and 110 received cloxacillin alone. We analyzed the primary endpoint with the intention-to-treat approach in 214 patients who received at least 1 day of treatment. Treatment success at day 7 after randomization was achieved in 83 (79.8%) of 104 patients receiving combination treatment versus 82 (74.5%) of 110 patients receiving monotherapy (risk difference 5.3%; 95% confidence interval (CI), \u20135.95\u201316.48). Secondary endpoints, including mortality and adverse events, were similar in the two groups except for persistent bacteremia at day 3, which was less common in the combination arm. In a prespecified interim analysis, the independent committee recommended stopping recruitment for futility prior to meeting the planned randomization of 366 patients. Cloxacillin plus fosfomycin did not achieve better treatment success at day 7 of therapy than cloxacillin alone in MSSA bacteremia. Further trials should consider the intrinsic heterogeneity of the infection by using a more personalized approach. ClinicalTrials.gov registration: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03959345\">NCT03959345<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41591-023-02569-0","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:02:13Z","timestamp":1696262533000},"page":"2518-2525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus\u2009aureus bacteremia: a randomized trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3596-8690","authenticated-orcid":false,"given":"Sara","family":"Grillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6475-6208","authenticated-orcid":false,"given":"Miquel","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3166-4016","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"L\u00f3pez-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorane","family":"Euba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Gasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4080-0008","authenticated-orcid":false,"given":"Lucia","family":"Boix-Palop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Garcia-Pa\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"P\u00e9rez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gomez-Zorrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Eduardo","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3446-1991","authenticated-orcid":false,"given":"Rafael","family":"San-Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Iftimie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Jover-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciano","family":"Garc\u00eda-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Izquierdo-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane Josune","family":"Goikoetxea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Gomila-Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Dietl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damaris","family":"Berbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-1379","authenticated-orcid":false,"given":"Sebastian","family":"Videla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Hereu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Padull\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Pallar\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Teb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Cuervo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3209-2563","authenticated-orcid":false,"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SAFO study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alba","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malen","family":"Aguirregabiria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regino","family":"Rodr\u00edguez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Blanco-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alguacil-Guillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Xercavins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Siverio-Par\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"de Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Moreno-Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Vasallo-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Borjabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Coloma-Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Clivill\u00e9-Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina Ximena","family":"Gonz\u00e1lez-di Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Tiago-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ru\u00edz-Basti\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Vizcarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"Ram\u00edrez-Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Bell\u00e9s-Bell\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Meije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"LLaberia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul Francisco","family":"Rigo-Bonnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrudis","family":"Horna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominica","family":"Mediavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Sanllorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Pic\u00f3-Plana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pitart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Sanchez-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"2569_CR1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SY Tong","year":"2015","unstructured":"Tong, S. Y., Davis, J. S., Eichenberger, E., Holland, T. L. & Fowler, V. G. Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 28, 603\u2013661 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"2569_CR2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","volume":"400","author":"GBD 2019 Antimicrobial Resistance Collaborators.","year":"2022","unstructured":"GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 2019. Lancet 400, 2221\u20132248 (2022).","journal-title":"Lancet"},{"key":"2569_CR3","doi-asserted-by":"publisher","first-page":"ofac653","DOI":"10.1093\/ofid\/ofac653","volume":"9","author":"TW van der Vaart","year":"2022","unstructured":"van der Vaart, T. W. et al. All-cause and infection-related mortality in Staphylococcus aureus bacteremia, a multicenter prospective cohort study. Open Forum Infect. Dis. 9, ofac653 (2022).","journal-title":"Open Forum Infect. Dis."},{"key":"2569_CR4","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1093\/cid\/ciz112","volume":"69","author":"M Souli","year":"2019","unstructured":"Souli, M. et al. Changing characteristics of Staphylococcus aureus bacteremia: results from a 21-year, prospective, longitudinal study. Clin. Infect. Dis. 69, 1868\u20131877 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"2569_CR5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/cid\/ciz018","volume":"69","author":"S Grillo","year":"2019","unstructured":"Grillo, S. et al. Impact of \u03b2-lactam and daptomycin combination therapy on clinical outcomes in methicillin-susceptible Staphylococcus aureus bacteremia: a propensity score-matched analysis. Clin. Infect. Dis. 69, 1480\u20131488 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"2569_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/cid\/ciz257","volume":"70","author":"E Minejima","year":"2020","unstructured":"Minejima, E. et al. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin. Infect. Dis. 70, 566\u2013573 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"2569_CR7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","volume":"20","author":"R Kuehl","year":"2020","unstructured":"Kuehl, R. et al. International Staphylococcus aureus collaboration study group and the ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis. Defining persistent Staphylococcus aureus bacteremia: secondary analysis of a prospective cohort study. Lancet Infect. Dis. 20, 1409\u20131417 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"2569_CR8","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1086\/598186","volume":"48","author":"GR Corey","year":"2009","unstructured":"Corey, G. R. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin. Infect. Dis. 48, S254\u2013S259 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"2569_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","volume":"68","author":"AJ Kaasch","year":"2014","unstructured":"Kaasch, A. J. et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J. Infect. 68, 242\u2013251 (2014).","journal-title":"J. Infect."},{"key":"2569_CR10","first-page":"118","volume":"88","author":"MA Sande","year":"1976","unstructured":"Sande, M. A. & Courtney, K. B. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. J. Lab. Clin. Med. 88, 118\u2013124 (1976).","journal-title":"J. Lab. Clin. Med."},{"key":"2569_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/archinte.1979.03630470016009","volume":"139","author":"JH Licht","year":"1979","unstructured":"Licht, J. H. Penicillinase-resistant penicillin\/gentamicin synergism: effect in patients with Staphylococcus aureus bacteremia. Arch. Intern. Med. 139, 1094\u20131098 (1979).","journal-title":"Arch. Intern. Med."},{"key":"2569_CR12","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/microorganisms10050848","volume":"10","author":"S Grillo","year":"2022","unstructured":"Grillo, S. et al. The effectiveness of combination therapy for treating methicillin-susceptible Staphylococcus aureus bacteremia: a systematic literature review and a meta-analysis. Microorganisms 10, 848 (2022).","journal-title":"Microorganisms"},{"key":"2569_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas, M. E., Vouloumanou, E. K., Samonis, G. & Vardakas, K. Z. Fosfomycin. Clin. Microbiol Rev. 29, 321\u2013347 (2016).","journal-title":"Clin. Microbiol Rev."},{"key":"2569_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00228-010-0794-5","volume":"66","author":"AC Kastoris","year":"2010","unstructured":"Kastoris, A. C., Rafailidis, P. I., Vouloumanou, E. K., Gkegkes, I. D. & Falagas, M. E. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur. J. Clin. Pharmacol. 66, 359\u2013368 (2010).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2569_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eimc.2018.05.009","volume":"37","author":"NM Coronado-\u00c1lvarez","year":"2019","unstructured":"Coronado-\u00c1lvarez, N. M., Parra, D. & Parra-Ruiz, J. Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocci. Enferm. Infecc. Microbiol. Clin. 37, 4\u201310 (2019).","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"2569_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cmi.2016.10.023","volume":"23","author":"PNA Harris","year":"2017","unstructured":"Harris, P. N. A. et al. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clin. Microbiol. Infect. 23, 533\u2013541 (2017).","journal-title":"Clin. Microbiol. Infect."},{"key":"2569_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","volume":"391","author":"GE Thwaites","year":"2018","unstructured":"Thwaites, G. E. et al. Adjunctive rifampicin for Staphylococcus aureus bacteremia (ARREST): a multicentre, randomized, double-blind, placebo-controlled trial. Lancet 391, 668\u2013678 (2018).","journal-title":"Lancet"},{"key":"2569_CR18","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1093\/cid\/ciaa1000","volume":"72","author":"MP Cheng","year":"2021","unstructured":"Cheng, M. P. et al. Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial. Clin. Infect. Dis. 72, e196\u2013e203 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"2569_CR19","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/cid\/ciac364","volume":"75","author":"TL Holland","year":"2022","unstructured":"Holland, T. L., Bayer, A. S. & Fowler, V. G. Persistent methicillin-resistant Staphylococcus aureus bacteremia: resetting the clock for optimal management. Clin. Infect. Dis. 75, 1668\u20131674 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"2569_CR20","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","volume":"72","author":"M Pujol","year":"2021","unstructured":"Pujol, M. et al. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial. Clin. Infect. Dis. 72, 1517\u20131525 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"2569_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","volume":"37","author":"A Florent","year":"2011","unstructured":"Florent, A., Chichmanian, R. M., Cua, E. & Pulcini, C. Adverse events associated with intravenous fosfomycin. Int. J. Antimicrob. Agents 37, 82\u201383 (2011).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2569_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/14787210.2017.1379897","volume":"15","author":"AF Shorr","year":"2017","unstructured":"Shorr, A. F., Pogue, J. M. & Mohr, J. F. Intravenous fosfomycin for the treatment of hospitalized patients with serious infections. Expert Rev. Anti Infect. Ther. 15, 935\u2013945 (2017).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"2569_CR23","doi-asserted-by":"publisher","first-page":"e051208","DOI":"10.1136\/bmjopen-2021-051208","volume":"11","author":"S Grillo","year":"2021","unstructured":"Grillo, S. et al. SAFO study group and the Spanish Network for Research in Infectious Diseases (REIPI). Multicentre, randomized, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteremia: study protocol for the SAFO trial. BMJ Open. 11, e051208 (2021).","journal-title":"BMJ Open."},{"key":"2569_CR24","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1001\/jama.2022.21243","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher, N. J. et al. Guidelines for reporting outcomes in trial protocols: The SPIRIT-outcomes 2022 extension. JAMA 328, 2345\u20132356 (2022).","journal-title":"JAMA"},{"key":"2569_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G. & Moher, D., CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. BMC Med. 8, 18 (2010).","journal-title":"BMC Med."},{"key":"2569_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","volume":"137","author":"ND Friedman","year":"2002","unstructured":"Friedman, N. D. et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 137, 791\u2013797 (2002).","journal-title":"Ann. Intern. Med."},{"key":"2569_CR27","unstructured":"Breakpoint tables for interpretation of MICs and zone diameters n.d. 2023, v 13.0 (European Committee on Antimicrobial Susceptibility Testing, accessed 18 March 2023); https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"2569_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cca.2017.03.009","volume":"468","author":"R Rigo-Bonnin","year":"2017","unstructured":"Rigo-Bonnin, R. et al. Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of \u03b2-lactam antibiotic concentration in human plasma. Clin. Chim. Acta 468, 215\u2013224 (2017).","journal-title":"Clin. Chim. Acta"},{"key":"2569_CR29","unstructured":"Guideline for good clinical practice. Current Step 4 version. 2016 (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, 2016; https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf)."},{"key":"2569_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A. et al. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377\u2013381 (2009).","journal-title":"J. Biomed. Inform."},{"key":"2569_CR31","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2017)."},{"key":"2569_CR32","unstructured":"dplyr: a grammar of data manipulation. R package v.1.0.10 (Wickham, H. et al., 2022)."},{"key":"2569_CR33","unstructured":"REDCapDM: \u2018REDCap\u2019 Data management. R package v. 0.1-0 (Carmezim, J., et al., 2022)"},{"key":"2569_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v057.i12","volume":"57","author":"I Subirana","year":"2014","unstructured":"Subirana, I., Sanz, H. & Vila, J. Building bivariate tables: the compareGroups package for R. J. Stat. Softw. 57, 1\u201316 (2014).","journal-title":"J. Stat. Softw."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02569-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02569-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02569-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:06:12Z","timestamp":1697450772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02569-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2569"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02569-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P. received a research grant from Laboratorios ERN. J.M.M. has received consulting honoraria and\/or research grants from Angelini Pharma, ContraFect, Genentech, Gilead Sciences, Janssen, Lysovant, Medtronic, Merck Sharp & Dohme (MSD), Novartis, Pfizer and ViiV Healthcare, outside the submitted work. J.L.C. has received speaker honoraria from Pfizer, MSD, AstraZeneca, Guerbet and Hartmann. L.E.L.C. has served as scientific advisor for Angelini Pharma, speaker for Angelini Pharma, ViiV Healthcare, Gilead Sciences and Correvio, and trainer for ViiV Healthcare. J.M.A. has received honoraria for speaking at symposia organised on behalf of Pfizer, Astellas, MSD, Angelini Pharma, Shionogi, Takeda and Gilead Sciences, and has sat on advisory boards on behalf of Pfizer, Astellas, MSD, Angelini Pharma, Gilead Sciences and Takeda. \u00c1.I.C. has received speaker honoraria from Pfizer, Bristol Myers Squibb, Esteve and Bayer. C.T. has received speaker honoraria from Gedeon Richter. G.C. has received support for attending national and international scientific congresses from Angelini Pharma Spain, Pfizer Spain and MSD, and speaker honoraria from Pfizer Spain and Gilead Sciences Europe. J.C. has received speaker honoraria from MSD and Gilead Sciences, and has participated as an investigator in trials on COVID-19 by Roche and Gilead Sciences. The rest of the authors do not declare any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}